Real-world efficacy of nivolumab plus cabozantinib in metastatic renal cell carcinoma (mRCC) using the IMDC.
Martín Zarbá(University of Calgary), Daniel Yick Chin Heng(University of Calgary), S Shamsi(University of Calgary), Zeynep İrem Özay(University of Utah), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Aurelius Omlin(University of Zurich), Lisa Ludwig(Centre Hospitalier Régional et Universitaire de Nancy), Kosuke Takemura(Japanese Foundation For Cancer Research), U. Vaishampayan(University of Michigan), Sumanta Kumar Pal(City of Hope), Martín Ángel(Instituto Alexander Fleming), Rashad Nawfal(Dana-Farber Cancer Institute), W. Y. Cheung(University of Calgary), Chiming Yang(Ipsen (France)), Parker Baumgarten(Alberta Cancer Foundation), J. Connor Wells(Occupational Cancer Research Centre), Razane El Hajj Chehade(Dana-Farber Cancer Institute), Federico Losco(Instituto Alexander Fleming), Toni K. Choueiri(Dana-Farber Cancer Institute), David Maj(University of Calgary)
Cited by 0
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Multiple primary tumours: challenges and approaches, a review
|ESMO Open|2017|616
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233